Natural History of New-onset Inflammatory Bowel Disease Among Patients With Multiple Sclerosis

Shiv Gandhi; Sara Zelman; Ricardo Eduardo De Armas; Christopher Hemond; Alexander N Levy; Siddharth Singh; Joshua Korzenik; Sushrut Jangi

doi:10.1093/ibd/izac053

Natural History of New-onset Inflammatory Bowel Disease Among Patients With Multiple Sclerosis

Inflamm Bowel Dis. 2022 Oct 3;28(10):1614-1617. doi: 10.1093/ibd/izac053.

Authors

Shiv Gandhi¹, Sara Zelman¹, Ricardo Eduardo De Armas², Christopher Hemond³, Alexander N Levy¹, Siddharth Singh⁴, Joshua Korzenik², Sushrut Jangi¹

Affiliations

¹ Division of Gastroenterology, Tufts Medical Center, Boston, MA, United States.
² Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA, United States.
³ Division of Neurology, University of Massachusetts Medical School, Worcester, MA, United States.
⁴ Division of Gastroenterology, University of California, La Jolla, CA, United States.

No abstract available

Keywords: Anti-TNF therapy; Autoimmune disease; Demyelination.

Plain language summary

Patients with MS and IBD were as likely to have stricturing, fistulizing, and extensive IBD as IBD controls. Although MS-IBD patients were less likely to initiate anti-TNF therapy, they did not have worsened risk of progression to surgery on follow-up.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Humans
Inflammatory Bowel Diseases* / complications
Infliximab
Multiple Sclerosis* / complications
Multiple Sclerosis* / epidemiology
Retrospective Studies
Tumor Necrosis Factor-alpha

Substances

Tumor Necrosis Factor-alpha
Infliximab

Plain language summary

Publication types

MeSH terms

Substances

Grants and funding